← All trials
NCT06053567
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Nov 14, 2023
- Primary completion
- Jun 30, 2027
- Completion date
- Jun 30, 2028
- First posted
- Sep 25, 2023
- Last posted
- Nov 15, 2023
- Enrollment
- 360
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- University of Texas, AustinLead sponsor
- National Cancer Institute (NCI)Collaborator
- Oklahoma State UniversityCollaborator
- University of HoustonCollaborator
- University of Texas, AustinOverall official - principal investigator
- University of Texas, AustinSponsor investigator
- YMCACollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.